Targeting Ewing Sarcoma With ANTI-IL1RAP Chimeric Antigen Receptor Modified Ex-Vivo Expanded Natural Killer Cells (CAR TGFBI-NK) and TGF-BETA Imprinted NK Cells (CAR TGFBI-NK) in Combination With Dinutuximab and NKTR-255
Author Type(s)
Faculty
Document Type
Abstract
Publication Date
6-2023
Journal Title
Pediatric Blood & Cancer
Department
Pathology, Microbiology and Immunology
Recommended Citation
Luo, W., Zhang, H., Hoang, H., Chu, Y., Ayello, J., Li, W., Scopim-Ribeiro, R., Lizardo, M. M., Rouleau, M., Dimitrov, D. S., Lee, D., Sorensen, P. H., & Cairo, M. S. (2023). Targeting Ewing Sarcoma With ANTI-IL1RAP Chimeric Antigen Receptor Modified Ex-Vivo Expanded Natural Killer Cells (CAR TGFBI-NK) and TGF-BETA Imprinted NK Cells (CAR TGFBI-NK) in Combination With Dinutuximab and NKTR-255. Pediatric Blood & Cancer, 70 (Suppl. 3), S205-S206. https://doi.org/10.1016/j.jbc.2023.103268
COinS
